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Abstract: 
Chronic obstructive pulmonary disease (COPD) is a complex multi-morbid disorder with 
significant cardiac mortality. Current cardiovascular risk prediction models do not include 
COPD. We investigated whether COPD modifies future cardiovascular risk to determine if it 
should be considered in risk prediction models.
Case-control study using baseline data from two randomized controlled trials performed 
between 2012 and 2015. Of the 90 eligible subjects, 26 COPD patients with lung 
hyperinflation were propensity matched for 10-year global cardiovascular risk score 
(QRISK2) with 26 controls having normal lung function. Patients underwent cardiac magnetic 
resonance imaging, arterial stiffness and lung function measurements. Differences in pulse 
wave velocity (PWV), total arterial compliance (TAC) and aortic distensibility were main 
outcome measures.
PWV (mean difference 1.0 m/s, 95% CI 0.02-1.92; p=0.033) and TAC (mean difference -0.27 
mL/m2/mmHg, 95% CI 0.39 -0.15; p<0.001) were adversely affected in COPD compared to 
the control group. The PWV difference equates to an age, sex and risk-factor adjusted 
increase in relative risk of cardiovascular events and mortality of 14% and 15%, respectively.
There were no differences in aortic distensibility. In the whole cohort (n=90) QRISK2 (β= 
0.045, p=0.005) was associated with PWV in multivariate analysis. The relationship between 
QRISK2 and PWV were modified by COPD, where the interaction term reached significance 
(p=0.014). FEV1 (β=0.055 (0.027), p=0.041) and pulse (B=-0.006 (0.002), p=0.003) were 
associated with TAC in multivariate analysis. 
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Markers of cardiovascular outcomes are adversely affected in COPD patients with lung 
hyperinflation compared to controls matched for global cardiovascular risk. Cardiovascular 
risk algorithms may benefit from the addition of a COPD variable to improve risk prediction 
and guide management. 
cardiovascular risk, surrogate markers, risk prediction models, pulse wave velocity, 
cardiovascular surrogate markers 
HAPPY London ClinicalTrials.gov: NCT01911910 and HZC116601; ClinicalTrials.gov: 
NCT01691885)
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Introduction
Chronic obstructive pulmonary disease (COPD) is predicted to be the third leading cause of 
death worldwide by 2020 [1]. It is a complex multi-morbid disorder in which up to 37% 
succumb to cardiovascular causes rather than respiratory failure [2]. The precise mechanisms 
contributing to cardiovascular risk in COPD are not yet fully elucidated but lung 
hyperinflation and systemic inflammation are postulated as possible mechanisms [3,4]. 
Predicting prognosis in COPD has proven difficult. Airflow limitation measured by the forced 
expiratory volume in 1 second (FEV1) in combination with airflow obstruction (FEV1/Forced 
vital capacity (FVC)) is the hallmark of COPD.  Used in isolation, these parameters only 
show weak association with all-cause mortality in COPD and therefore been combined in 
multi-dimensional risk assessments to improve predictive value [5,6]. It has been suggested 
that a reduction in FEV1, combined with a smoking history is a better predictor of 
cardiovascular mortality than cholesterol [7]. Despite this, the current global cardiovascular 
risk scores, which use algorithms  for estimating cardiovascular risk, and have been 
developed and advocated by cardiovascular prevention guidelines to communicate risk and 
facilitate treatment decisions [8-10], do not factor in COPD severity, raising the possibility 
that risk estimation may be sub-optimal [11]. 
Aortic distensibility, total arterial compliance (TAC) and left ventricular mass (LVM) have 
been identified as cardiac magnetic resonance (CMR) surrogates of cardiovascular risk, a 
modality which provides unparalleled image quality non-invasively with excellent accuracy 
and reproducibility [12-14]. Carotid-femoral pulse wave velocity (PWV), a non-invasive 
bedside measure of global arterial stiffness, is also an independent predictor of coronary 
artery disease [13,15,16]. 
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The aim of this study was to assess whether differences exist in cardiovascular surrogate 
markers in COPD compared to controls with normal lung function, when matched for global 
cardiovascular risk. We hypothesize that differences exist and COPD may be considered as a 
cardiovascular risk factor. 
Material and methods
Patients
This post-hoc case-control analysis utilized baseline data from two randomized controlled 
trials undertaken between November 2012 to May 2015 at our center with matched protocol 
for assessed parameters. Patients were propensity matched by QRISK2 score ± 2% (a United 
Kingdom based validated 10-year cardiovascular risk algorithm) [17]. All participants gave 
written informed consent. The study was approved by the national Research Ethics Committee 
(NRES committee – London) and was conducted in accordance with the declaration of Helsinki. 
Participants were consented for use of data different from those of the original study.
COPD group
The COPD group consisted of 45 consecutive patients recruited to a clinical trial involving 
stable hyperinflated COPD patients [18]. The diagnosis of COPD was confirmed according to 
published criteria using the lower limit of normal for FEV1 and ratio of FEV1 to FVC for all 
COPD patients [19]. Patients were aged over 40 years with at least 15 pack-year smoking 
history and evidence of lung hyperinflation on body plethysmograph (residual volume >120 
% of predicted) with no history of COPD exacerbation in the preceding 4 weeks. All patients 
with known cardiovascular disease (7 individuals) or atrial fibrillation (2 individuals) were 
excluded, leaving 36 evaluable hyperinflated COPD patients. There was a washout period of 
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at least 48 hours for long acting beta-2 agonists, 4 days for long acting muscarinic antagonists 
and at least 6 hours for the short acting bronchodilators prior the CMR and PVW assessments.
Control group with known cardiovascular risk
The control group was drawn from imaging subgroup of 96 out of the total of study 
population of 402 participants with global 10-year cardiovascular risk of 10% based on 
QRISK2, recruited to the Heart Attack Prevention Programme for You (HAPPY) London 
primary prevention randomized controlled trial aiming to reduce cardiovascular risk in a 
cohort free of pre-existing cardiovascular disease [20]. Only those that underwent CMR 
imaging with normal spirometry and absence of respiratory disease or atrial fibrillation were 
included, leaving 54 evaluable subjects. 
Spirometry
Spirometry was performed using equipment meeting the minimum performance 
recommendations of the American Thoracic Society/European Respiratory Society task force 
(Microlab3500, Micromedical,UK) [21]. At least 3 valid spirometry efforts were attempted, 
but no more than 8. Residual volume, total lung capacity and functional residual capacity 
z-scores for the COPD group were calculated from published reference ranges[22].
Static lung volumes, measured using whole body plethysmography (ZAN500, Germany) 
and carbon monoxide transfer factor, via a single breath hold technique (CPL PFT, 
United States), were assessed according to manufacturers’ instructions [18].
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Cardiovascular magnetic resonance
CMR images were analyzed from baseline scans performed on a 1.5T CMR system (Achieva, 
Philips, Netherlands) using a Software release 3.2 and Cardiac package installed. ISS 
performed analysis for the COPD group, while MYK performed analysis for the control 
group. Ventricular (both groups) and atrial (COPD group only) volumes and function data 
were acquired according to local protocol and international guidance [24]. All participants 
were specifically advised to refrain from caffeine, alcohol and smoking for at least 8 hours 
prior to the CMR and PWV assessments. The endocardial contours of the ventricle and atria 
were manually segmented and summed for the whole ventricle using semi-automated 
software (CVI42, Circle Cardiovascular imaging Inc, Calgary, Canada) to quantify end-
diastolic (EDV), end-systolic volumes (ESV), ejection fraction and stroke volume (SV) for 
the left atrium and both left (LV) and right (RV) ventricles. Values were indexed (denoted by 
letter “I”) to body surface area as determined by the Mosteller formula [25]. Cardiac Index 
was calculated according to the following formula: SVI x pulse. Epicardial contours were 
manually segmented at end-diastole for the left ventricle to allow the calculation of indexed 
LV mass (LVMI). 
Local arterial stiffness: CMR aortic distensibility measurements
Two SSFP cine images were acquired during end-expiration in planes perpendicular to the 
thoracic aorta at the level of the pulmonary artery (thoracic ascending aorta (TAA) and 
thoracic descending aorta (TDA), with further image acquired 10cm below this for the 
abdominal aorta (ABA). Brachial blood pressure was measured using a CMR compatible 
oscillatory sphygmomanometer (Vicorder, Skidmore medical, UK) and central blood pressure 
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estimated using a validated transfer function used in calculating distensibility where 
distensibility (%/mmHg) = [(maximum area– minimum area)/pulse pressure x minimum area] 
x 100 [26],[27]. Minimum and maximum values for cross sectional areas were derived using 
an in-house validated automated endoluminal border-tracking program written in MatLab 
(v.7.5).
Global arterial stiffness: Pulse wave velocity and total arterial compliance
PWV were obtained using Vicorder device as described previously. according to 
manufacturer’s guidelines [28]. Briefly, for PWV measurements the path-length was 
calculated from the suprasternal notch to a defined point on the upper part of the femoral cuff. 
The foot-to-foot transit time (TT) was measured as described previously and values for 
cfPWV were derived automatically [29]. Measurements were performed in a supine position, 
after 10 minutes rest, outside the CMR scanner and prior to lung function maneuvers. All 
measurements were repeated at least twice and the mean value of consistent measures was 
derived. TAC was derived by the following formula: SVI / central pulse pressure
Statistics
Matching of the groups was performed using SAS (SAS Institute Inc., Cary, NC, US, Version 
9.3). Patients were matched by QRISK2 score ± 2% to test the initial hypothesis. Statistical 
analysis was performed using SPSS 21.0 for Mac (SPSS Inc., Chicago, Illinois, USA). The 
distribution of the data was assessed visually. Continuous variables were expressed as mean ± 
SD for parametric variables and median (interquartile range) for non-parametric variables. 
Differences between the COPD and controls were assessed using paired t-tests. Univariate 
followed by multivariate linear regression analysis was used to evaluate associations between 
patient variable and the surrogate endpoints that showed differences between the groups. 
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Cohort adjusted effects were obtained by including COPD status as a factor in the models. 
Variables for inclusion in the multivariate models were selected using all-subsets variable 
selection using the Bayesian information criterion to select the final model. A term for COPD 
status was forced in to all models to account for differences between the two studies. Models 
were validated using 5-fold cross validation repeated 100 times. Where an association was 
found, further regression analyses were performed on the interaction terms to establish 
whether the presence or absence of COPD as a binary variable had any impact on the 
relationship between QRISK2 and the cardiovascular surrogates. Thus, the matched design 
was used initially to look at differences between the two groups. Subsequently, we performed 
a multivariate analysis using all the data from both cohorts and further analysed the data to 
control for variables that were different between the two groups (including hypertension, 
diabetes and smoking). The extent of intra-observer agreement was assessed using Bland-
Altman method on 20 randomly selected patients (10 from each cohort) for the CMR 
measures and on 16 of the HAPPY London cohort for Vicorder measures of PWV and aortic 
pulse pressure [30]. Statistical significance was defined as a two-sided p<0.05.
Results
Of the 36 eligible COPD patients 26 were successfully matched for 10-year global 
cardiovascular risk ± 2% based on QRISK2 score with 26 of the 54 HAPPY London 
participants with normal lung function. Baseline demographics and pulmonary function of the 
52 matched individuals are shown in Table 1. As expected, there were no differences in 
QRISK2 score (p=0.693), age (p=0.447), sex (p=0.161), blood pressure (p=0.447), renal 
function (p=0.055) or cholesterol treatment (p=0.449) between the groups. The control group 
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had a higher prevalence of diabetes, whilst the COPD group had more impaired pulmonary 
function and significant smoking history leading to similar QRISK2 scores.
Inter-observer agreement
The Bland Altman plots (eFigure 1) confirmed acceptable agreement between ISS and MYK 
measurements of PWV (bias 0.43 m/s, limits of agreement (LOA) -0.9, 1.76, Intra-class 
correlation coefficient (ICC) 90.5 %), aortic pulse pressure (bias -1.14 mmHg, LOA -22.9, 
23.2, ICC 86.4 %), aortic relative area change (thoracic ascending aorta (TAA) bias 9.3 x 10-
3, LOA -0.06, 0.82, ICC 80.2 %; thoracic descending aorta (TDA) bias 1.4 x 10-3, LOA -
0.02,0.02, ICC 97.9 %; abdominal aorta (ABA) bias -2.9 x 10-3 LOA -0.02, 0.03, ICC 99.2 %) 
left ventricle end-diastolic volume index (LVEDVI) (bias -3.6 ml/m2 LOA-12.5, 5.8, ICC 
96.6 %), left ventricular mass index (LVMI) (bias -2.9 g/m2, LOA -13.65, 7.83, ICC 87.5 %) 
and LVSVI (bias 2.0 ml/m2 LOA -2.5, 8.5, ICC 92.5 %).
Arterial stiffness
Global arterial stiffness measures of PWV and TAC were adversely affected in COPD 
compared to the matched control group. PWV was higher in the COPD group compared to 
controls with a mean difference of 1.0 m/s (95% CI 0.1, 1.9; p=0.033), whereas TAC was 
lower by -0.27 mL/m2/mmHg (95% CI -0.4, -0.2; p<0.001 (Table 2; Figure 1).
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Local arterial stiffness measured using aortic distensibility, although numerically lower in 
COPD compared to controls in all 3 regions analyzed, showed no statistical differences (mean 
difference TAA: -0.41 %/mmHg x10-3 95% CI -0.9, 0.1, p=0.088; TDA -0.29 %/mmHg x10-3 
95% CI -0.8, 0.2 p=0.216; ABA -0.27%/mmHg x10-3 95% CI -1.2, 0.6, p=0.536).
Ventricular mass, size and function
No differences in LVMI were identified between groups (mean difference 2.8 g/m2; 95% CI -
2.5, 8.1, p=0.291) (Table 2). Chamber size was smaller in COPD group compared to the 
controls with mean differences in LVEDVI and RVEDVI of -14.1 ml/m2 (95% CI -22.1, - 6.3 
p=0.001) and -13.0 (95% CI -23.9, -2.9 P=0.022) respectively. There was a corresponding 
lower LVSVI (mean difference -10.3 ml/m2 95% CI -15.4, -5.3, p<0.001) but no differences 
in LV ejection fraction. Despite lower stroke volume, cardiac index was similar as a 
consequence of a higher heart rate in the COPD group (76±14 vs. 63±11 beats/min, p=0.001).
Baseline demographics and pulmonary function for the COPD and control groups making up 
the 90-patient cohort are shown in eTable 1. The results of the univariate and multivariate 
analyses for PWV and TAC for the whole 90 patients are show  in Table 3 and Table 4, 
respectively. In the first model (where QRISK2 is entered but age, sex and SBP are excluded) 
QRISK2 was associated with PWV in the multivariate analysis, whereby a 10% increase in 
QRISK2 was associated with 0.45 m/s higher PWV when adjusting for other co-variates in 
the model. However, the relationship between QRISK2 and PWV differed when stratified 
according to presence or absence of COPD (COPD group r2=0.260; control group r2=0.003 
which was significant when an interaction term was included in the model (p=0.014) (Figure 
1A).
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In the second multivariate model (which includes age, sex and SBP but not QRISK2), age and 
SBP enter the model. A ten-year increase in age is associated with a 0.7 m/s higher PWV, 
while a 10mmHg increase in SBP results in a 0.30 m/s higher PWV. There is a significant 
interaction between SBP and COPD group (p=0.019). A 10mmHg increase in SBP associated 
with a significant (0.40 m/s, SE=0.08) increase for COPD, with no significant effect (0.07 
m/s, SE=0.12) for controls. The R2 for the model including the interaction term is 49.3%, 
suggesting a better fit with the individual components of age and SBP in the model rather than 
QRISK2 (R2=21.5%). Differences remained significant between the COPD and control 
groups following sensitivity analysis to control for the baseline differences (eTable 2).
Discussion
The principle novel findings of our study are that PWV and TAC, known independent 
predictors of cardiovascular disease, are adversely affected in stable hyperinflated COPD over 
and above a cohort considered to have equivalent global cardiovascular risk but normal lung 
function. There appears to be an interaction between COPD and QRISK2 with regard to its 
relationship to PWV.
Concerns have previously been raised about the accuracy of a number of different scoring 
systems and possible over-estimation of risk in the general population [31]. We have found 
PWV in our COPD cohort to be  1.0 m/s higher than in matched non-COPD subjects which 
would equate to an age, sex and risk-factor adjusted increase in relative risk of cardiovascular 
events and mortality of 14% and 15%, respectively [32,33]. Furthermore, we have shown a 
clear interaction between COPD and the QRISK2 in relation to PWV (Fig 1). COPD has an 
estimated UK prevalence of 13.5% in those over 35 years of age and when assessing 
cardiovascular risk in this group using smoking status alone may not optimally predict 
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cardiovascular risk in this common disease. Whilst it has been shown that the addition of 
Framingham risk score to FEV1 improves risk stratification for cardiovascular events 
compared to FEV1 alone, our findings importantly suggest that the inclusion of COPD may 
improve the predictive ability of cardiovascular risk scores and should be further confirmed in 
larger population studies [34]. Secondly, this interaction implies that COPD could potentially 
act as a modifiable risk factor. This is a concept supported by previous post-hoc analyses of 
large randomized controlled trials and two more recent randomized controlled trials where the 
treatment of COPD with conventional therapies have led to a reduction in PWV [35-38]. 
The impact of blood pressure in COPD patients appears to be exaggerated based on our 
findings and suggests the need for tighter control in this group for primary prevention of 
cardiovascular events, although randomized controlled trials in this area are lacking [39]. 
Non-pharmacological treatment (including increased physical activity and smoking cessation) 
and antihypertensive medication need to be integral in the reduction of future CVD in this 
group. Relying on current CVD risk scoring systems alone, such as QRISK2, may not 
optimally identify high-risk individuals who may not receive guideline based treatments that 
are based on risk thresholds [11]. 
Mechanisms proposed for the association between PWV and COPD include systemic 
inflammation and the effects of hyperinflation on neurohumoral activation [3]. Computed 
tomography defined emphysema has been associated with PWV, whilst reports linking 
systemic inflammation to PWV in COPD have been inconsistent [40]. Sabit et al found 
relationships with Interleukin (IL)-6, whereas a more recent study found no relationship with 
leukocytes, C-reactive protein, IL-6, IL-8 or soluble tumor necrosis factor receptor pathway 2. 
Whilst we also found no relationship with leucocytes, we have found a relationship between 
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PWV and fibrinogen, a marker of systemic inflammation in both COPD and cardiovascular 
disease [41,42]. An accurate understanding of the role of fibrinogen in the relationship 
between COPD and cardiovascular disease is under evaluation, but if confirmed could act as a 
potential therapeutic target [43]. 
TAC has been shown to be a predictor of cardiovascular events, in normal individuals free 
from cardiovascular disease, hypertensives and elderly [44,45]. However, unlike PWV we 
found no relationship with QRISK2 in univariate or multivariate analysis. Arterial stiffness 
measures are surrogate measures of end-organ disease representing an index of the summed 
effects of aging and exposure. However, these surrogate measures have varying abilities to 
predict particular types of cardiovascular events. Whilst the QRISK2 score is designed to 
predict both the risk of myocardial infarction and stroke, TAC when measured using CMR 
has been shown to be independently associated with non-fatal cardiac events only, including 
hospitalization for congestive heart failure and arrhythmia [14]. This may in part explain the 
lack of relationship.
We have confirmed the findings of previous studies, which were limited by lacking suitable 
control groups and/or the inclusion of patient populations with more severe disease, that 
COPD patients have smaller cardiac chambers and stroke volumes, and maintain cardiac 
output through a compensatory increase in heart rate [46-49]. The cause of the smaller cardiac 
chamber size is thought to be a pre-load effect [46,47,50,51]. Our group has previously 
demonstrated that lung deflation in the short-term result in at least partial reversal of these 
effects, with decompression of the cardiac chambers, improvements in stroke volume, cardiac 
output and atrial ejection fraction [23]. Long term implications of these findings on heart 
failure and arrhythmia, increased in COPD, are as yet unknown, but may identify another 
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therapeutic target for the prevention of cardiac co-morbidity in COPD [52]. At present COPD 
remains a risk factor for heart failure mortality and has been incorporated into risk scores 
accordingly [53]. The findings presented here add weight to the belief that the same should 
considered for cardiovascular risk. COPD prevalence is higher than rheumatoid arthritis, a 
condition which is already included in QRISK2 score. An estimated 1 million COPD patients 
in the UK alone are undiagnosed [32]. The inclusion of COPD could potentially improve risk 
estimation, provision of lifestyle advise and intervention[54], and promote the early diagnosis 
of COPD through increased usage of pulmonary function testing and the availability of 
pulmonary function data on primary and secondary care databases.
Limitations
The results have to be interpreted in the context of the study design. This is a post-hoc cross-
sectional analysis so we are able to establish association but not causation. Given the 
relatively small sample size these findings should be interpreted with caution and replicated 
on a larger scale. The COPD cohort in our study all had RV>120% of predicted, thus further 
research is required to see if the results can be generalized to patients with milder COPD, 
lower RV or those with differing clinical phenotypes. Although the COPD and control group 
were matched for global cardiovascular risk, it is difficult to accurately quantify the impact of 
the variations in individual risk factors and medication use on the outcome measures. Our 
primary purpose was to investigate the applicability of cardiovascular risk scores to patients 
with COPD by way of assessing surrogates of cardiac risk and as such our investigation 
regarding the proposed mechanisms surrounding increased risk have not been exhaustive.
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Conclusion
PWV and TAC are adversely affected in hyperinflated COPD compared to a group matched 
for global cardiovascular risk. The relationship between cardiovascular risk scores and PWV 
appears to be modified by COPD. Further research is needed to assess if CVD risk algorithms 
may benefit from the addition of a COPD variable to improve risk prediction and guide 
management, given its common occurrence and associated high cardiovascular morbidity and 
mortality.
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Figure Legends
Figure 1 Differences in pulse wave velocity, total arterial compliance and their 
relationship to QRISK2 in COPD compared to controls matched for cardiovascular risk
Figure 1 Legend
Markers of cardiovascular outcomes adversely affected in COPD patients compared to 
controls matched for global cardiovascular risk.
eFigure 1
Bland-Altman plots showing agreement between measurements a) Left ventricular end 
diastolic volume index (LVEDVI), b) Central pulse pressure, c) Left ventricular stroke 
volume index (LVSVI), d) Thoracic ascending aorta pulsatility, e) Left ventricular mass 
index, f) Pulse wave velocity, g) Abdominal aorta pulsatility and h) Thoracic descending 
aorta pulsatility.
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Table 1 Demographic and pulmonary function characteristics of COPD and control 
groups matched for global cardiovascular risk
Notes: Plus–minus values are means ± SD. * Denotes p-value of <0.05 † The QRISK2 score is a 
validated global cardiovascular risk score which predicts the likelihood of a myocardial infarction 
Variable Control group matched for 
cardiovascular risk (n=26)
COPD (n=26) P 
10-year global cardiovascular 
risk (QRISK2) score†, %
19.3±6.9 18.6±7.0 0.693
Age, yrs 63.7±5.1 64.9±7 0.447
Male n (%) 21 (81) 17 (65) 0.161
Pulse, beats/min 63±11 76±14 0.001*
eGFR, mL/min/1.73m2 89±18 78±20 0.055
Brachial SBP, mmHg 134±12 138±23 0.447
Brachial DBP, mmHg 82±10 79±11 0.221
Hypertension treatment, n (%) 16 (61) 9 (35) 0.050
Cholesterol treatment, n (%) 15 (58) 12 (46) 0.449
Diabetes, n (%) 7 (27) 0 (0) 0.006*
Smoking, pack years 5±10 44±36 <0.001*
FEV1, L 3.20±0.74 1.42±0.60 <0.001*
FEV1/FVC 0.75±0.05 0.47±0.14 <0.001*
FEV1  Z score 0.107±1.030 -3.192±0.888 <0.001*
FEV1/FVC Z score -0.391±0.758 -3.515±1.045 <0.001*
Residual volume, L - 3.85±0.96 -
Residual volume, % predicted - 170±37 -
Residual volume Z-score - 3.632±2.021 -
Total lung capacity Z-score - 0.653±1.757 -
Functional residual capacity 
Z-score
- 2.431±1.871 -
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2
or cerebrovascular accident in the next 10 years based on routinely collected data from National 
Health Service general practitioner databases in the United Kingdom. 
Abbreviations: DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FEV1, 
forced expiratory volume in 1 second; FVC, forced vital capacity; HT, hypertension; LLN. 
Lower limit of normal SBP, systolic blood pressure, SD, standard deviation.  
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Table 2 Comparison of cardiovascular endpoints between COPD and control group matched for global cardiovascular risk
Variable Control group matched 
for cardiovascular risk 
(n=26)
COPD
(n=26)
Mean difference of 
COPD vs control 
group (95% CI )
P
Cardiac volumes, mass and function
LVEDVI, mL/m2 77.7±12.2 63.6±15.7 -14.1(-22.1, -6.1) 0.001*
LVESVI, mL/m2 28.7±7.7 24.9±7.5 -3.8(-7.9, 0.2) 0.062
LVSVI, mL/m2 49.0±6.9 38.7±10.1 -10.3(-15.4, -5.3) <0.001*
Cardiac Index mL/min/m2 3079±607 2868±610 -211(-560.5, 138.4) 0.225
LVEF, % 63.4±5.4 61.0±6.5 -2.5(-5.6, 0.6) 0.115
LVMI, g/m2 50.0±7.9 52.7±8.5 2.8(-2.5, 8.1) 0.291
RVEDVI mL/m2 90.5±17.6 77.5±19.5 -13.0(-23.9, -2.0) 0.022*
Vascular function; global measures
PWV, m/s 8.0±1.9 9.0±1.4 1.0(0.1, 1.9) 0.033*
Total Arterial Compliance, 
mmHg/ml/m2
0.950±0.19 0.680±0.24 -0.27(-0.4, -0.2) <0.001*
Vascular function; local measures
Aortic distensibility, %/mmHg x10-3
Thoracic ascending aorta 2.01±0.9 1.59±1.0 -0.41(-0.9, 0.1) 0.088
Thoracic descending aorta 2.24±1.0 1.95±0.8 -0.29(-0.8, 0.2) 0.216
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Notes: Data expressed as mean±SD. 
Indexed values are calculated as raw values divided by body surface area. *Denotes p-value of <0.05
Abbreviations: CI: confidence interval; COPD: chronic obstructive pulmonary disease; LVEDVI: left ventricle end diastolic volume 
index; LVEF: left ventricle ejection fraction: LVESVI: left ventricle end systolic volume index; LVMI, left ventricle mass index; 
LVSVI: left ventricle stroke volume index; PWV: carotid-femoral pulse wave velocity; RVEDVI: right ventricle end diastolic volume 
index. 
Abdominal aorta 3.27±1.2 3.00±1.8 -0.27(-1.2, 0.6) 0.536
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Table 3 Univariate and cohort adjusted predictors of pulse wave velocity and total arterial 
compliance
¶ One outlier from the total cohort of 90 (PWV=16.3) is excluded from the model leaving 89 
subjects
Abbreviations:  Β, unstandardized beta co-efficient; eGFR, estimated glomerular filtration rate; 
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity
Variable Pulse wave velocity m/s 
Univariate Cohort adjusted
Whole Cohort n=89¶ Β (se) P-value Β (se) P-value
Age, yrs 0.087 (0.017) <0.001 0.089 (0.016) 0.001
Sex (male) -0.328 (0.301) 0.279 -0.196 (0.298) 0.512
Diabetes -0.519 (0.395) 0.192 -0.198 (0.410) 0.630
QRISK2, % 0.039 (0.016) 0.017 0.045 (0.016) 0.005
Pulse, beats/min 0.014 (0.010) 0.155 0.006 (0.010) 0.570
Systolic blood pressure, 
mmHg
0.039 (0.007) <0.001 0.038 (0.007) <0.001
eGFR, mL/min/1.73m2 -0.007 (0.008) 0.392 -0.005 (0.007) 0.547
FEV1, Z-score -0.155 (0.071) 0.033 0.028 (0.145) 0.849
FEV/FVC, Z score -0.137 (0.079) 0.086 0.204 (0.168) 0.227
Variable Total Arterial Compliance mmHg/ml/m2
Whole Cohort n=90 Univariate Cohort adjusted
Β (se) P-value Β (se) P-value
Age, yrs -0.010 (0.004) 0.022 -0.011 (0.004) 0.003
Sex (male) 0.263 (0.064) <0.001 0.208 (0.058) <0.001
Diabetes 0.174 (0.090) 0.058 0.029 (0.085) 0.730
QRISK2, % -0.003 (0.004) 0.490 -0.005 (0.003) 0.129
Pulse, beats/min -0.010 (0.002) <0.001 -0.007 (0.002) <0.001
Systolic blood pressure, 
mmHg
-0.005 (0.002) 0.008 -0.005 (0.002) 0.003
eGFR, mL/min/1.73m2 0.002 (0.002) 0.148 0.001 (0.001) 0.337
FEV1, Z score 0.086 (0.014) <0.001 0.060 (0.029) 0.043
FEV/FVC, Z score 0.085 (0.016) <0.001 0.028 (0.035) 0.422
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Table 4 Multivariate predictors of pulse wave velocity and total arterial compliance
¶ One outlier from the total cohort of 90 (PWV=16.3) is excluded from the model leaving 89 
subjects
# Including QRISK2, excluding age, sex, SBP, diabetes as potential predictors as they are 
included in the composite score.
^ Including age, sex, SBP, diabetes among potential predictors in multivariate model (but not 
QRISK2)
Abbreviations:  Β, unstandardized beta co-efficient; eGFR, estimated glomerular filtration rate; 
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity
Variable Pulse wave velocity m/s
Multivariate (cohort 
forced in to model)#
Multivariate (cohort 
forced in to model)^
Whole Cohort n=89¶ R2=15.7% R2=45.9%
Β (se) P-value Β (se) P-value
COPD:Control 0.824 (0.267) 0.003 0.735 (0.214) 0.001
Age, years - - 0.072 (0.015) <0.001
Sex (male) - - - -
Diabetes - - - -
QRISK2, % 0.045 (0.016) 0.005 - -
Pulse, beats/min - - - -
Systolic blood pressure, 
mmHg
- - 0.030 (0.007) <0.001
eGFR, mL/min/1.73m2 - - - -
FEV1,  Z score - - - -
FEV/FVC, Z score - - - -
Total Arterial Compliance mmHg/ml/m2
Multivariate (cohort 
forced in to model)#
Multivariate (cohort 
forced in to model)^
Whole Cohort n=90 R2=38.1% R2=49.4%
Β (se) P-value Β (se) P-value
COPD:Control -0.066 (0.108) 0.541 -0.054 (0.100) 0.592
Age, years - - -0.010 (0.003) 0.004
Sex (male) - - 0.138 (0.054) 0.013
Diabetes - - - -
QRISK2, % - - - -
Pulse, beats/min -0.007 (0.002) 0.001 -0.006 (0.002) 0.003
Systolic blood pressure, 
mmHg
- - - -
eGFR, mL/min/1.73m2 - - - -
FEV1, Z score 0.053 (0.028) 0.058 0.055 (0.027) 0.041
FEV/FVC, Z score - - - -
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Figure 1 Differences in pulse wave velocity, total arterial compliance and their relationship to QRISK2 in 
COPD compared to controls matched for cardiovascular risk. Markers of cardiovascular outcomes adversely 
affected in COPD patients compared to controls matched for global cardiovascular risk. 
254x190mm (96 x 96 DPI) 
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1
Online supplementary data
Chronic Obstructive Pulmonary Disease as a Predictor of Cardiovascular Risk: 
A Case-Control Study
eTable 1. Demographic and pulmonary function characteristics of all eligible 
patients from the COPD cohort and HAPPY London cohort used in univariate 
and multivariate analyses
Variable COPD group
n=36
Control group
n=54
10-year global cardiovascular risk (QRISK2) score*, % 17.0±10.2 19.2±7.0
Age, yrs 63±9 64±6
Male n (%) 21(58) 41 (76)
Pulse, beats/min 72±16 62±11
eGFR, mL/min/1.73m2 80±20 85±19
Brachial SBP, mmHg 133±22 132±12
Brachial DBP, mmHg 77±11 79±9
Hypertension treatment, n (%) 9(25) 29(54)
Cholesterol treatment, n (%) 13(36) 33(61)
Diabetes, n (%) 0(0) 13(24)
Smoking, pack years 47±33 7±10
FEV1, L 1.39±0.62 3.16±0.81
FEV1/FVC 0.45±0.13 0.74±0.04
FEV1 Z-score -3.343±0.980 0.655±1.266
FEV1/FVC Z-score -3.678±0.993 -0.155±0.813
Residual volume, L 3.74±1.90 -
Residual volume, % predicted 172±37 -
Residual volume Z-score 3.736±1.896
Total lung capacity Z-score 0.851±1.567
Functional residual capacity Z-score 2.591±1.741
Abbreviations: DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; FEV1: forced expiratory volume in 1 
second; FVC: forced vital capacity; HT: hypertension; LLN: lower limit of normal, SBP: systolic blood pressure, SD: standard 
deviation.  Plus–minus values are means ± SD. * The QRISK2 score is a validated global cardiovascular risk score which 
predicts the likelihood of a myocardial infarction or cerebrovascular accident in the next 10-years based on routinely collected 
data from National Health Service general practitioner databases in the United Kingdom. 
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2
eTable 2: Sensitivity analysis for confounding factors - comparison of results from matched data and total cohort. 
Abbreviations: COPD: chronic obstructive pulmonary disease; PWV: pulse wave velocity; SBP: systolic blood pressure; 
Matched cohort
Vascular function; global 
measures
Mean ± SD
Controls, n=26
Mean ± SD
COPD, n=26
Mean difference (95% 
CI )
P
PWV 8.0±1.9 9.0±1.4 1.0 (0.1, 1.9) 0.033*
Total Arterial Compliance 0.950±0.19 0.680±0.24 -0.27 (-0.4, -0.2) <0.001*
TOTAL COHORT
Adjusted for age, sex, cholesterol, SBP, hypertension and diabetes.
Vascular function; global 
measures
Mean ± SD
Controls, n=54
Mean ± SD
COPD, n=36
Mean difference (95% 
CI )
P
PWV 7.8±1.0 8.5±1.1 0.7 (0.2, 1.1) 0.006*
Total Arterial Compliance 0.985 ±0.24 0.680±0.25 -0.28 (-0.39, -0.17) <0.001*
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e Figure 1 
Bland-Altman plots showing agreement between measurements a) Left ventricular end diastolic volume 
index (LVEDVI), b) Central pulse pressure, c) Left ventricular stroke volume index (LVSVI), d) Thoracic 
ascending aorta pulsatility, e) Left ventricular mass index, f) Pulse wave velocity, g) Abdominal aorta 
pulsatility and h) Thoracic descending aorta pulsatility. 
201x264mm (72 x 72 DPI) 
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STROBE Statement—Checklist of items that should be included in reports of case-
control studies 
Item 
No Recommendation
Page 
No
(a) Indicate the study’s design with a commonly used term in the title 
or the abstract
1&3Title and abstract 1
(b) Provide in the abstract an informative and balanced summary of 
what was done and what was found
3
Introduction
Background/rationale 2 Explain the scientific background and rationale for the investigation 
being reported
4
Objectives 3 State specific objectives, including any prespecified hypotheses 6&7
Methods
Study design 4 Present key elements of study design early in the paper 7
Setting 5 Describe the setting, locations, and relevant dates, including periods 
of recruitment, exposure, follow-up, and data collection
7
(a) Give the eligibility criteria, and the sources and methods of case 
ascertainment and control selection. Give the rationale for the choice 
of cases and controls
7&8Participants 6
(b) For matched studies, give matching criteria and the number of 
controls per case
7
Variables 7 Clearly define all outcomes, exposures, predictors, potential 
confounders, and effect modifiers. Give diagnostic criteria, if 
applicable
8&9
Data sources/ 
measurement
8*  For each variable of interest, give sources of data and details of 
methods of assessment (measurement). Describe comparability of 
assessment methods if there is more than one group
8&9
Bias 9 Describe any efforts to address potential sources of bias 9&10
Study size 10 Explain how the study size was arrived at 10
Quantitative 
variables
11 Explain how quantitative variables were handled in the analyses. If 
applicable, describe which groupings were chosen and why
10
(a) Describe all statistical methods, including those used to control for 
confounding
10
(b) Describe any methods used to examine subgroups and 
interactions
9&10
(c) Explain how missing data were addressed N/A
(d) If applicable, explain how matching of cases and controls was 
addressed
7
Statistical methods 12
(e) Describe any sensitivity analyses 10
Results
(a) Report numbers of individuals at each stage of study—eg numbers 
potentially eligible, examined for eligibility, confirmed eligible, included 
in the study, completing follow-up, and analysed
7
(b) Give reasons for non-participation at each stage N/A
Participants 13*
(c) Consider use of a flow diagram N/A
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, 10 
Page 38 of 39
URL: http:/mc.manuscriptcentral.com/copd
COPD: Journal Of Chronic Obstructive Pulmonary Disease
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
2
social) and information on exposures and potential confounders and 
Table 
1
(b) Indicate number of participants with missing data for each variable 
of interest
N/A
Outcome data 15* Report numbers in each exposure category, or summary measures of 
exposure
10
(a) Give unadjusted estimates and, if applicable, confounder-adjusted 
estimates and their precision (eg, 95% confidence interval). Make 
clear which confounders were adjusted for and why they were 
included
10-
12
(b) Report category boundaries when continuous variables were 
categorized
N/A
Main results 16
(c) If relevant, consider translating estimates of relative risk into 
absolute risk for a meaningful time period
N/A
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and 
sensitivity analyses
11-
12
Discussion
Key results 18 Summarise key results with reference to study objectives 12
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias 
or imprecision. Discuss both direction and magnitude of any potential bias
14
Interpretation 20 Give a cautious overall interpretation of results considering objectives, 
limitations, multiplicity of analyses, results from similar studies, and other 
relevant evidence
10-
12
Generalisability 21 Discuss the generalisability (external validity) of the study results 15
Other information
Funding 22 Give the source of funding and the role of the funders for the present study 
and, if applicable, for the original study on which the present article is based
17
*Give information separately for cases and controls.
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological 
background and published examples of transparent reporting. The STROBE checklist is best used in 
conjunction with this article (freely available on the Web sites of PLoS Medicine at 
http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at 
http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-
statement.org.
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